Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: A prospective, multicenter, open-label, randomized, two-way crossover drug—drug interaction study
References (51)
- et al.
Enhancement of radiosensitivity by proteasome inhibition: Implications for a role of NF-kappaB
Int J Radiat Oncol Biol Phys.
(2001) - et al.
VELCADE/ dexamethasone (Vel/D) versus VAD as induction treatment prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM): Updated results of the IFM 2005/01 trial. Blood. ASH Annual Meeting Abstracts
Blood.
(2007) - et al.
Bortezomib (Velcade)-thalidomide-dexamethasone (VTD) vs thalidomide-dexamethasone (TD) in preparation for autologous stem- cell (SC) transplantation (ASCT) in newly diagnosed multiple myeloma (MM). ASH Annual Meeting Abstracts
Blood.
(2007) - et al.
Drug-drug interactions in oncology: Why are they important and can they be minimized?
Crit Rev Oncol Hematol.
(2005) - et al.
BiRD (Biaxin [clarithromycin]/Revlimid [lenaldomide]/dexamethasone) combination therapy results in high complete- and overallresponse rates in treatment-naive symptomatic multiple myeloma
Blood.
(2008) - et al.
United States Food and Drug Administration approval summary: Bortezomib for the treatment of progressive multiple myeloma after one prior therapy
Clin Cancer Res.
(2006) - et al.
Bortezomib for the treatment of mantle cell lymphoma
Clin Cancer Res.
(2007) VELCADE (bortezomib) for injection [prescribing information]
(2008)- et al.
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
N Engl J Med.
(2008) - et al.
Proteasome inhibition as a novel therapeutic target in human cancer
J Clin Oncol.
(2005)
The proteasome as a target for cancer therapy
Clin Cancer Res.
(2003)
PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis
Mol Cancer Ther.
(2002)
Proteasome inhibitors: A novel class of potent and effective antitumor agents
Cancer Res.
(1999)
26S Proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer
J Cell Biochem.
(2001)
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma
Br J Haematol.
(2004)
A phase 2 study of bortezomib in relapsed, refractory myeloma
N Engl J Med.
(2003)
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma
J Clin Oncol.
(2006)
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
N Engl J Med.
(2005)
MMY-3002: A phase 3 study comparing bortezomib-melphalan-prednisone (VMP) with melphalan-prednisone (MP) in newly diagnosed multiple myeloma. ASH Annual Meeting Abstracts
Blood.
(2007)
A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies
Clin Cancer Res.
(2002)
Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgenindependent prostate cancer
J Clin Oncol.
(2004)
Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer
J Clin Oncol.
(2005)
Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors
Clin Cancer Res.
(2006)
A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors
Cancer.
(2006)
Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors
Cancer.
(2006)
Cited by (59)
A simplified method for bortezomib determination using dried blood spots in combination with liquid chromatography/tandem mass spectrometry
2021, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life SciencesPharmacology differences among proteasome inhibitors: Implications for their use in clinical practice
2021, Pharmacological ResearchCitation Excerpt :These combinations should be therefore avoided, or the dose of bortezomib adjusted and patients monitored for efficacy [54,55]. Ketoconazole was found to increase bortezomib exposure by 35% and patients taking bortezomib with potent CYP3A inhibitors should be monitored for ADRs [55,56]. Patients receiving bortezomib plus ciclosporin should also be monitored for symptoms of neuropathy and the treatment schedule should be re-evaluated in the case of worsening of peripheral neuropathy [55].
The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges
2020, Pharmacology and TherapeuticsNext-generation proteasome inhibitors for cancer therapy
2018, Translational ResearchBlood distribution of bortezomib and its kinetics in multiple myeloma patients
2014, Clinical Biochemistry
- *
Current affiliation: Translational Genomics Research Institute, Scottsdale, Arizona.
- †
Current affiliation: Emory University School of Medicine, Winship Cancer Institute, Atlanta, Georgia.
Copyright © 2009 Excerpta Medica Inc. All rights reserved.